We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Boston Scientific on Acquisition Spree

By HospiMedica staff writers
Posted on 15 Mar 2001
Following its agreement to acquire Interventional Technologies in mid-February for US$345 million, Boston Scientific (Natick, MA, USA) has recently acquired or agreed to acquire three more companies.

Boston Scientific has acquired Embolic Protection, Inc. More...
(EPI, Campbell, CA, USA) for $75 million. EPI has developed an embolic protection device, which is mounted on a guidewire and used to capture embolic material that is dislodged during cardiovascular interventions. The acquisition allows Boston Scientific to enter the embolic protection market, which it believes is one of the most promising new growth segments in interventional medicine.

Catheter Innovations (Salt Lake City, UT, USA) has also been acquired by Boston Scientific, expanding the latter's holdings in the $500 million venous access market. Terms were not disclosed. Catheter Innovations develops and markets catheter-based venous access products used for the delivery of chemotherapy drugs, antibiotics, and nutritional support. The company offers a complete line of products that incorporate its Pressure-Activated Safety Valve (PASV) protection technology. This acquisition will complement the less-invasive offerings of the Medi-tech division of Boston Scientific.

Boston Scientific has agreed to acquire Quanam Medical Corp. (Santa Clara, CA, USA). Quanam develops medical devices using novel polymer technology, with a focus on drug-delivery stent systems for use in cardiovascular applications. Terms were not disclosed. Quanam's drug-delivery stent incorporating a paclitaxel derivative is in a pivotal clinical trial in Europe. Boston Scientific also has a paclitaxel-coated stent in clinical trials in Europe.



Related Links:
Boston Scientific

Gold Member
12-Channel ECG
CM1200B
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Resorbable Bovine Collagen Membrane
GenDerm
New
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.